Artiva Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Artiva Biotherapeutics

07/08/2026 01:12

Artiva Biotherapeutics Inc ARTV.OQ reported a quarterly adjusted loss of 63 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -87 cents.  The mean expectation of six analysts for the quarter was for a loss of 62 cents per share. Wall Street expected results to range from -80 cents to -43 cents per share.
Reported revenue was zero​; analysts expected zero. 
Artiva Biotherapeutics Inc's reported EPS for the quarter was a loss of 63 cents​.
The company reported a quarterly loss of $25.01 million.
Artiva Biotherapeutics Inc shares had risen by 19.5% this quarter and gained 170.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 19.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." 
Wall Street's median 12-month price target for Artiva Biotherapeutics Inc is $40.00, about 71.1% above its last closing price of $11.58
This summary was machine generated from LSEG data August 7 at 12:12 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.62
-0.63
Missed
Mar. 31 2026 
-0.87
-0.95
Missed
Dec. 31 2025 
-0.83
-0.85
Missed
Sep. 30 2025 
-0.87
-0.88
Missed